FMP
89bio Shares Up 10% Since Q4 Earnings Announcement
Mar 15, 2023 9:39 AM - Davit Kirakosyan(Last modified: Dec 19, 2023 5:49 PM)
Image credit: FMP
89bio, Inc. (NASDAQ:ETNB) shares rose more than 10% since the company’s reported Q4 results on Friday. R&D came in at $19.1 million and SG&A was $6.3 million. Cash and equivalents ended the quarter at $188.2 million. The company reiterated the March timeline for key ph.IIb pegoza NASH data.
Analysts at RBC Capital said they expect similar data to AKRO's FGF21 analog and believe this will lead to a meaningful stock upside. According to the analysts, pivotal studies in SHTG, an underappreciated opportunity with a low-risk path, remain on track and provide a high valuation floor. The analysts continue to see an attractive buying opportunity into the upcoming data.
Other Blogs
Oct 31, 2023 8:03 AM - Parth Sanghvi
FCFF vs FCFE: What's the Difference?
Free cash flow to the firm (FCFF) and free cash flow to equity (FCFE) are two of the most important metrics used in financial modeling. Both metrics measure the amount of cash that is available to a company's shareholders and creditors, but there is a key difference between the two. FCFF measures...
Nov 25, 2023 6:39 AM - Parth Sanghvi
DCF Valuation vs. Comparable Companies Analysis: Choosing the Right Valuation Method
Choosing the Right Valuation Method: DCF vs. Comparable Companies Analysis Introduction: Valuation methods play a pivotal role in determining the fair value of a company, aiding investors in making informed investment decisions. Two commonly used methods, DCF Valuation and Comparable Companies A...
Dec 23, 2023 2:19 AM - Parth Sanghvi
Understanding the Limitations of DCF Analysis: A Guide to Overcoming Challenges
Introduction: Discounted Cash Flow (DCF) analysis stands as a cornerstone in valuing investments, yet its efficacy is contingent upon various assumptions and methodologies. While a powerful tool, DCF analysis comes with inherent limitations and challenges that investors must acknowledge to make i...
